gettyimages-934451976.jpg
Op-Ed

Strangely enough, young blood is now for sale at Ambrosia

Ambrosia is a startup founded by a Stanford Medical School graduate who wants you to wire him $12,000 on PayPal for two liters of young people’s blood. What a strange, strange world.

In Greek myth, ambrosia was the drink of the gods, a wondrous elixir that could make those who consumed it immortal. In 2019, Ambrosia is a startup founded by a Stanford Medical School graduate who wants you to wire him $12,000 on PayPal for two liters of young people’s blood. What a strange, strange world.

According to the company’s website (and the latest report on the saga from Erin Brodwin for Business Insider), Ambrosia is now open for business. The company’s mission sounds like a Peter Thiel fever dream: It buys blood plasma that comes from donors between the ages of 16 and 25, then conducts intravenous infusions to pump that blood into the veins of older clients. This is supposed to help customers live longer and better lives, or something, but the proof that it works is at best negligible and at worst nonexistent. Fear not, though: On its website, under the heading “Science,” Ambrosia offers a thorough defense of its techniques:


I mean, you can’t argue with that. Assuming you’re sold, Ambrosia now lists five locations where interested parties can schedule treatments, namely Los Angeles; San Francisco; Houston; Tampa, FL; and Omaha, NE. It costs $8,000 to be infused with one liter of blood, or $12,000 for two liters. This is all the brainchild of Jesse Karmazin, who, Business Insider helpfully notes, “is not a licensed medical practitioner.”

It’s established science that blood transfusions can save lives in certain situations. It’s not so established whether young blood (what an uncomfortable phrase to be typing so frequently) can help defeat Father Time—let alone whether it’s a good idea to let amateurs inject blood into your veins. As the company’s website indicates, a groundbreaking study showed possible benefits in mice, but when it comes to humans, that evidence is lacking. Ambrosia conducted a clinical trial on the efficacy of its treatments on dozens of paying volunteers; the company says it will make the results public at some point, although it hasn’t yet.

Whether the results of that trial will be worthwhile is another question entirely. The design of the trial raised major questions among medical researchers, with the fact that participants were paying thousands of dollars and the lack of a placebo arm among their very reasonable-seeming concerns.

But let’s put all that aside. Let’s say you’re convinced that Ambrosia is the answer to the problems of aging. Let’s say you’re interested in paying five figures for an experimental medical procedure without first consulting a doctor. Let’s say you’re one of the hundred-plus people who reportedly reached out to Ambrosia upon the initial launch of the company’s website in September. Is this a screenshot that inspires confidence?


Who among us hasn’t wanted to add a couple liters of blood to the shopping cart. If nothing else, Peter Thiel would appreciate the PayPal integration.

This article represents the author’s views and doesn’t necessarily represent the views of PitchBook.

Learn about our editorial standards.